# BioCardia Inc. (BCDA)

Source: https://www.quantisnow.com/company/BCDA
Generated: 2026-11-10T08:30:58.904Z

- Ticker: BCDA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0000925741
- Website: biocardia.com

## About

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.

## Latest BCDA news and filings

- 2026-11-09 21:18 UTC [Earnings Date] [BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026](https://www.quantisnow.com/insight/biocardia-to-host-q3-2026-financial-results-and-corporate-update-6781544)
- 2026-11-06 13:30 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-other-events-financial-statements-6778165)
- 2026-11-06 13:30 UTC [BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application](https://www.quantisnow.com/insight/biocardia-completes-clinical-consultation-process-with-japans-pmda-for-cardiamp-6778149)
- 2026-10-20 21:42 UTC [Insider Buy] [President and CEO Altman Peter bought $475 worth of shares (500 units at $0.95) (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-475-worth-of-shares-6752497)
- 2026-10-19 13:15 UTC [BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter](https://www.quantisnow.com/insight/biocardia-announces-fda-acceptance-of-de-novo-pre-submission-package-for-6750228)
- 2026-10-19 13:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by BioCardia Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-biocardia-inc-6749987)
- 2026-10-07 13:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by BioCardia Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-biocardia-inc-6739979)
- 2026-10-07 13:00 UTC [BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting](https://www.quantisnow.com/insight/biocardia-presents-cardiamp-hf-ii-trial-design-at-heart-failure-6739940)
- 2026-10-01 13:15 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-other-events-financial-statements-6731807)
- 2026-10-01 13:15 UTC [BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter](https://www.quantisnow.com/insight/biocardia-files-revised-de-novo-pre-submission-for-fda-approval-of-6731801)
- 2026-09-30 22:51 UTC [Insider Buy] [President and CEO Altman Peter bought $1,030 worth of shares (1,000 units at $1.03), increasing direct ownership by 0.26% to 384,885 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-1030-worth-of-shares-6731076)
- 2026-09-24 00:14 UTC [Insider Buy] [President and CEO Altman Peter bought $1,995 worth of shares (1,900 units at $1.05), increasing direct ownership by 0.50% to 383,885 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-1995-worth-of-shares-6724596)
- 2026-09-23 13:15 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-other-events-financial-statements-6723900)
- 2026-09-23 13:15 UTC [BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission](https://www.quantisnow.com/insight/biocardia-confirms-timing-and-provides-update-on-fda-helix-pre-submission-6723893)
- 2026-09-21 20:30 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-other-events-6721807)
- 2026-09-10 12:30 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-other-events-financial-statements-6710989)
- 2026-09-10 12:30 UTC [BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/biocardia-to-present-cardiamp-regulatory-and-corporate-progress-at-hc-6710962)
- 2026-09-05 01:30 UTC [Insider Buy] [President and CEO Altman Peter bought $872 worth of shares (800 units at $1.09), increasing direct ownership by 0.21% to 381,985 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-872-worth-of-shares-6707120)
- 2026-08-24 12:30 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6692215)
- 2026-08-24 12:30 UTC [BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval](https://www.quantisnow.com/insight/biocardia-announces-fda-confirms-helix-transendocardial-delivery-catheter-meeting-minutes-6692193)
- 2026-08-21 20:34 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-notice-of-delisting-or-6691520)
- 2026-08-18 16:14 UTC [Insider Buy] [President and CEO Altman Peter bought $5,022 worth of shares (5,400 units at $0.93), increasing direct ownership by 1% to 381,115 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-5022-worth-of-shares-6686260)
- 2026-08-13 21:43 UTC [Insider Buy] [President and CEO Altman Peter bought $1,748 worth of shares (1,900 units at $0.92), increasing direct ownership by 0.51% to 375,785 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-1748-worth-of-shares-6681394)
- 2026-08-12 20:27 UTC [SEC Form 8-K] [BioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biocardia-inc-filed-sec-form-8-k-results-of-operations-and-6678149)
- 2026-08-12 20:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioCardia Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-biocardia-inc-6677930)
- 2026-08-12 20:05 UTC [Earnings Date] [BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results](https://www.quantisnow.com/insight/biocardia-reports-second-quarter-2026-business-highlights-and-financial-results-6677747)
- 2026-08-05 19:16 UTC [Earnings Date] [BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026](https://www.quantisnow.com/insight/biocardia-to-host-q2-2026-financial-results-and-corporate-update-6664706)
- 2026-07-30 01:05 UTC [Insider Buy] [President and CEO Altman Peter bought $3,900 worth of shares (5,000 units at $0.78), increasing direct ownership by 1% to 373,885 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-3900-worth-of-shares-6654495)
- 2026-07-20 20:16 UTC [Insider Buy] [President and CEO Altman Peter bought $415 worth of shares (500 units at $0.83), increasing direct ownership by 0.14% to 368,885 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-415-worth-of-shares-6642523)
- 2026-07-15 20:40 UTC [Insider Buy] [President and CEO Altman Peter bought $3,754 worth of shares (4,300 units at $0.87), increasing direct ownership by 1% to 368,385 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-3754-worth-of-shares-6638480)
- 2026-07-10 22:18 UTC [Insider Buy] [President and CEO Altman Peter bought $7,175 worth of shares (7,500 units at $0.96), increasing direct ownership by 2% to 369,485 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-7175-worth-of-shares-6634517)
- 2026-07-08 19:30 UTC [Insider Buy] [President and CEO Altman Peter bought $5,208 worth of shares (5,400 units at $0.96), increasing direct ownership by 2% to 361,985 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-bought-5208-worth-of-shares-6631411)
- 2026-07-08 02:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Stertzer Simon H](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stertzer-simon-h-6630684)
- 2026-07-08 02:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Slosman Marvin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-slosman-marvin-6630683)
- 2026-07-08 02:03 UTC [SEC Form 4] [President and CEO Altman Peter covered exercise/tax liability with 54,606 shares, decreasing direct ownership by 13% to 356,585 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-altman-peter-covered-exercisetax-liability-with-54606-6630681)
- 2026-07-08 02:03 UTC [SEC Form 4] [Chief Financial Officer Mcclung David covered exercise/tax liability with 23,125 shares, decreasing direct ownership by 17% to 114,245 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-mcclung-david-covered-exercisetax-liability-with-23125-6630680)
- 2026-07-08 02:02 UTC [SEC Form 4] [Senior Vice President, Devices Gillis Edward M covered exercise/tax liability with 17,269 shares, decreasing direct ownership by 24% to 54,126 units (SEC Form 4)](https://www.quantisnow.com/insight/senior-vice-president-devices-gillis-edward-m-covered-exercisetax-liability-6630679)
- 2026-07-08 02:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Blank Andrew Scott](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-blank-andrew-scott-6630678)
- 2026-07-08 01:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Allen Jim L.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-allen-jim-l-6630677)
- 2026-07-08 01:44 UTC [SEC Form 4] [SEC Form 4 filed by Director Moyes Jay M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-moyes-jay-m-6630676)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BCDA
- Earnings history: https://www.quantisnow.com/earnings/BCDA
- Dividend history: https://www.quantisnow.com/dividends/BCDA
- Insider transactions: https://www.quantisnow.com/insiders/BCDA
- Options chain: https://www.quantisnow.com/options/BCDA
- SEC 8-K filings only: https://www.quantisnow.com/company/BCDA/8-k
- RSS and alerts for BCDA: https://www.quantisnow.com/docs/rss-feeds.md